Shyndec Pharma divests subsidiary stake for RMB 155m
Shanghai Shyndec Pharmaceutical announced the sale of its 51% stake in Guoyao Hasen (Shangqiu) Pharmaceutical for a minimum bid price of RMB 155,192,541 through the Shanghai United Assets and Equity Exchange.
The subsidiary has posted continuous losses since 2021 due to limited product scale and intense market competition. Guoyao Hasen's net assets were audited at RMB 152,027,800 as of April 30, 2025, with an appraised value of RMB 304,299,100.
The divestment allows Shyndec to focus on core businesses and optimize resource allocation.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Shanghai Shyndec Pharmaceutical publishes news
Free account required • Unsubscribe anytime